ATE437369T1 - Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen - Google Patents

Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen

Info

Publication number
ATE437369T1
ATE437369T1 AT04756257T AT04756257T ATE437369T1 AT E437369 T1 ATE437369 T1 AT E437369T1 AT 04756257 T AT04756257 T AT 04756257T AT 04756257 T AT04756257 T AT 04756257T AT E437369 T1 ATE437369 T1 AT E437369T1
Authority
AT
Austria
Prior art keywords
enzyme
nucleic acid
immunohistological
epitopes
enhanced
Prior art date
Application number
AT04756257T
Other languages
English (en)
Inventor
Christopher Bieniarz
Casey A Kernag
Jerome W Kosmeder
Paula M Rodgers
Jennifer Wong
Original Assignee
Ventana Med Syst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of ATE437369T1 publication Critical patent/ATE437369T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/093Polyol derivatives esterified at least twice by phosphoric acid groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
AT04756257T 2003-06-24 2004-06-24 Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen ATE437369T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48259603P 2003-06-24 2003-06-24
PCT/US2004/020700 WO2005003777A2 (en) 2003-06-24 2004-06-24 Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences

Publications (1)

Publication Number Publication Date
ATE437369T1 true ATE437369T1 (de) 2009-08-15

Family

ID=33563868

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04756257T ATE437369T1 (de) 2003-06-24 2004-06-24 Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen

Country Status (10)

Country Link
US (1) US7632652B2 (de)
EP (1) EP1636586B1 (de)
JP (1) JP4648902B2 (de)
AT (1) ATE437369T1 (de)
AU (1) AU2004254386B2 (de)
CA (2) CA2530287C (de)
DE (1) DE602004022165D1 (de)
DK (1) DK1636586T3 (de)
ES (1) ES2330441T3 (de)
WO (1) WO2005003777A2 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691598B2 (en) * 2001-03-30 2010-04-06 Nanoprobes, Inc. Method for detecting a target molecule by metal deposition
US7888060B2 (en) * 2001-03-30 2011-02-15 Nanoprobes, Inc. Method for detecting a target using enzyme directed deposition of elemental metal
US7642064B2 (en) * 2003-06-24 2010-01-05 Ventana Medical Systems, Inc. Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest
CA2609702C (en) 2005-04-28 2013-05-28 Ventana Medical Systems, Inc. Antibody conjugates via heterobifunctional peg linkers
CA2631005C (en) * 2005-11-23 2017-02-28 Ventana Medical Systems, Inc. Molecular conjugate
DK2442107T3 (da) 2006-11-01 2014-05-19 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til deres fremstilling og anvendelse
JP4920553B2 (ja) * 2006-11-08 2012-04-18 富士フイルム株式会社 イムノクロマトグラフキット
CA2687178C (en) 2007-05-23 2014-02-04 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
FR2924601A1 (fr) * 2007-12-07 2009-06-12 Oreal Composes diphosphate d'hydroquinone et leur utilisation pour depigmenter la peau.
CA2720728C (en) 2008-06-05 2018-04-03 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
DK2334827T3 (da) 2008-08-22 2015-06-15 Ventana Med Syst Inc Metode til kromogen påvisning af to eller flere målmolekyler i en enkelt prøve
KR101027036B1 (ko) * 2009-05-28 2011-04-11 주식회사 인포피아 금 이온의 환원에 의한 측방유동 분석에서의 신호 증폭 방법 및 이를 이용한 측방유동 분석 디바이스
BR112012016233A2 (pt) 2009-12-31 2017-03-07 Ventana Med Syst Inc métodos para produzir uma sonda de ácido nucleico, sonda de ácido nucleico isolado e kit
DK2539355T3 (da) 2010-02-26 2017-01-02 Ventana Med Syst Inc IN-SITU-hybridisering med polytag-prober
ES2636908T3 (es) 2010-04-27 2017-10-10 Ventana Medical Systems, Inc. Conjugados de nanopartícula-anticuerpo y procedimientos para producir y usar dichos conjugados
EP2588144B1 (de) 2010-07-02 2018-05-09 Ventana Medical Systems, Inc. Nachweis von zielmolekülen mit massenmarkierungen und massenspektrometrie
US9103762B2 (en) 2010-10-28 2015-08-11 Eth Zurich Method for electrical detection of biomolecules by metal dissolution and Assay kit therefore
EP2659000B1 (de) 2010-12-30 2016-08-10 Ventana Medical Systems, Inc. Verbesserte ablagerung von chromogenen mit pyrimidinanaloga
US8703439B1 (en) 2011-01-31 2014-04-22 Linda Lester Point of care iodine sensor
CN103534359B (zh) 2011-03-14 2016-07-06 文塔纳医疗系统公司 分析染色体易位的方法及其系统
WO2012151111A1 (en) 2011-05-04 2012-11-08 Htg Molecular Diagnostics, Inc. Quantitative nuclease protection assay (qnpa) and sequencing (qnps) improvements
WO2013167387A1 (en) 2012-05-10 2013-11-14 Ventana Medical Systems, Inc. Uniquely specific probes for pten, pik3ca, met, top2a, and mdm2
ES2648176T3 (es) 2012-07-12 2017-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos de predicción del tiempo de supervivencia y de la respuesta al tratamiento de un paciente que padece un cáncer sólido con un distintivo de al menos 7 genes
WO2014048942A1 (en) 2012-09-25 2014-04-03 Ventana Medical Systems, Inc. Probes for pten, pik3ca, met, and top2a, and method for using the probes
WO2014145458A1 (en) 2013-03-15 2014-09-18 Arizona Board Of Regents On Behalf Of Arizona State University Nucleic acid-tagged compositions and methods for multiplexed protein-protein interaction profiling
WO2015036405A1 (en) 2013-09-10 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating basal cell carcinoma
WO2015069787A1 (en) 2013-11-05 2015-05-14 Htg Molecular Diagnostics, Inc. Methods for detecting nucleic acids
JP6825915B2 (ja) 2014-02-24 2021-02-03 ヴェンタナ メディカル システムズ, インク. 標識された2’−o−メチルrnaオリゴヌクレオチドプローブ及びシグナル増幅系を使用する自動rna検出
JP6626097B2 (ja) 2014-06-06 2019-12-25 ヴェンタナ メディカル システムズ, インク. 乳がんにおける腫瘍内her2不均質性の意義及びそのための使用
AU2015326827B2 (en) 2014-10-02 2019-11-07 Ventana Medical Systems, Inc. Polymers and conjugates comprising the same
EP3009147A1 (de) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur Behandlung von resistenten Glioblastomen
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
WO2016146654A1 (en) 2015-03-16 2016-09-22 Ventana Medical Systems, Inc. Materials and methods for detecting androgen receptor splice variants and uses thereof
WO2016166169A1 (en) 2015-04-17 2016-10-20 Spring Bioscience Corporation Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
WO2016189065A1 (en) 2015-05-26 2016-12-01 Ventana Medical Systems, Inc. Method and system for assessing stain quality for in-situ hybridization and immunohistochemistry
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
EP3408410B1 (de) 2016-01-26 2023-12-20 Ventana Medical Systems, Inc. Prädiktiver diagnostischer arbeitsfluss für tumore mithilfe automatisierter dissektion, sequenzierung der nächsten generation und automatisierte objektträgerfärber
CA3016555A1 (en) 2016-03-08 2017-09-14 Ventana Medical Systems, Inc. Multiplexed immunohistochemistry using recombinant antibodies with epitope tags
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
WO2017202962A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
WO2018011107A1 (en) 2016-07-11 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of er-alpha 46 in methods and kits for assessing the status of breast cancer
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018055080A1 (en) 2016-09-22 2018-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
EP3516397A1 (de) 2016-09-23 2019-07-31 Ventana Medical Systems, Inc. Verfahren und systeme zur bewertung extrazellulärer matrixbiomarker in tumorproben
WO2018091419A1 (en) 2016-11-15 2018-05-24 Ventana Medical Systems, Inc. Compositions and methods for prognosing and treating colorectal cancer
EP3555622B1 (de) 2016-12-19 2023-02-22 Ventana Medical Systems, Inc. Verfahren und systeme zur quantitativen immunhistochemie
CN110121364A (zh) 2016-12-19 2019-08-13 文塔纳医疗系统公司 肽核酸缀合物
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
WO2018146239A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018162404A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Biomarker for outcome in aml patients
WO2018172540A1 (en) 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to predict the progression of alzheimer's disease
WO2018189215A1 (en) 2017-04-12 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from hepatocellular carcinoma
CN107189988B (zh) * 2017-07-17 2019-08-30 江南大学 一株分泌抗丁香酚单克隆抗体的杂交瘤细胞株cs12及其应用
WO2019020556A1 (en) 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. METHODS AND SYSTEMS FOR ASSESSING INFILTRAT OF IMMUNE CELLS IN TUMOR SAMPLES
WO2019038219A1 (en) 2017-08-21 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) NEW PROGNOSTIC METHOD OF PANCREATIC CANCER
WO2019043138A1 (en) 2017-09-01 2019-03-07 INSERM (Institut National de la Santé et de la Recherche Médicale) METHOD FOR PREDICTING OUTCOME OF CANCER
EP3692368A1 (de) 2017-09-25 2020-08-12 Institut National de la Sante et de la Recherche Medicale (INSERM) Verwendung von vnn1 als biomarker und therapeutisches target bei sarkomen
JP2021507695A (ja) 2017-12-18 2021-02-25 ヴェンタナ メディカル システムズ, インク. ペプチド核酸コンジュゲート
DK3746790T3 (da) 2018-01-31 2023-12-11 Ventana Med Syst Inc Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019224153A1 (en) 2018-05-21 2019-11-28 Genentech, Inc. Her2 heterogeneity as a biomarker in cancer
WO2020016266A1 (en) 2018-07-17 2020-01-23 Ventana Medical Systems, Inc. Materials and methods for detecting fusion proteins
WO2020053376A1 (en) 2018-09-13 2020-03-19 Ventana Medical Systems, Inc. Histochemical and cytochemical methods for detecting ntrk fusion proteins
WO2020072348A1 (en) 2018-10-01 2020-04-09 Ventana Medical Systems, Inc. Methods and systems for predicting response to pd-1 axis directed therapeutics
WO2020089432A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
WO2020089428A1 (en) 2018-11-02 2020-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New prognostic method of pancreatic cancer
EP3884259A1 (de) 2018-11-20 2021-09-29 Ventana Medical Systems, Inc. Verfahren und systeme zur herstellung und analyse von zellulären proben für morphologische merkmale und biomarkerexpression
WO2020141199A1 (en) 2019-01-03 2020-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
WO2020148349A1 (en) 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Variants of erythroferrone and their use
WO2020161125A1 (en) 2019-02-05 2020-08-13 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
US20220098674A1 (en) 2019-02-13 2022-03-31 Inserm (Institut National De La Santé Et Dr La Recherch Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020182932A1 (en) 2019-03-13 2020-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) New gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
EP3959340A1 (de) 2019-04-24 2022-03-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur vorhersage der reaktion von antipsychotischen wirkstoffen
WO2020229521A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
WO2021044012A1 (en) 2019-09-05 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
WO2021074391A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US20230113705A1 (en) 2020-02-28 2023-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
WO2021186014A1 (en) 2020-03-20 2021-09-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the survival time of a patient suffering from a cancer
CN115552248A (zh) 2020-05-07 2022-12-30 文塔纳医疗系统公司 用于评价肿瘤样品中egfr和egfr配体表达的组织化学系统和方法
US20230250426A1 (en) 2020-06-10 2023-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and prognosing cancer like glioblastoma
US20230218608A1 (en) 2020-06-18 2023-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2022018163A1 (en) 2020-07-22 2022-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting survival time in patients suffering from cancer
EP4217399A1 (de) 2020-09-22 2023-08-02 Roche Diagnostics GmbH Antikörper spezifisch für alpha-1,6-kern-fucosyliertes psa und fucosylierte fragmente davon
WO2022064049A1 (en) 2020-09-28 2022-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing brucella infection
WO2022084327A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response to tnf inhibitors
EP4240874A1 (de) 2020-11-06 2023-09-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur diagnose und behandlung des polyzystischen ovarialsyndroms (pcos)
WO2022135753A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022136252A1 (en) 2020-12-21 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for prognosis the humoral response of a subject prior to vaccination
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
WO2022171611A1 (en) 2021-02-09 2022-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to pronostic lung cancer
WO2022194949A1 (en) 2021-03-17 2022-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing pancreatic cancer
WO2022207566A1 (en) 2021-03-29 2022-10-06 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to evaluate pancreatic cancer prognosis
EP4326903A1 (de) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Verfahren und zusammensetzungen zur behandlung von krankheiten im zusammenhang mit zellalterungsansammlung
WO2023280790A1 (en) 2021-07-05 2023-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2023152133A1 (en) 2022-02-08 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for diagnosing colorectal cancer
WO2024061930A1 (en) 2022-09-22 2024-03-28 Institut National de la Santé et de la Recherche Médicale New method to treat and diagnose peripheral t-cell lymphoma (ptcl)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491098A (en) 1987-03-09 1996-02-13 Janssen Pharmaceutica N.V. Method for depositing metal particles on a marker
FR2680374B1 (fr) 1988-03-25 1993-11-12 Bioprobe Systems Sa Procede de coloration d'acides nucleiques detectes par marquage non radioactif et ensemble de reactifs pour la mise en óoeuvre de ce procede.
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5116734A (en) 1989-09-01 1992-05-26 Digene Diagnostics, Inc. Highly sensitive method for detecting peroxidase
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5595707A (en) 1990-03-02 1997-01-21 Ventana Medical Systems, Inc. Automated biological reaction apparatus
WO1992010092A1 (en) 1990-12-06 1992-06-25 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5355439A (en) 1991-08-05 1994-10-11 Bio Tek Instruments Method and apparatus for automated tissue assay
US5696887A (en) 1991-08-05 1997-12-09 Biotek Solutions, Incorporated Automated tissue assay using standardized chemicals and packages
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
EP0624059A4 (en) 1991-11-22 1994-12-21 Affymax Technologies N.V. Combinatorial strategies for polymer synthesis.
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
DE69503126T2 (de) 1994-05-05 1998-11-12 Beckman Instruments Inc Repetitive oligonukleotide matrix
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6165734A (en) * 1995-12-12 2000-12-26 Applied Spectral Imaging Ltd. In-situ method of analyzing cells
US6093574A (en) 1997-08-11 2000-07-25 Ventana Medical Systems Method and apparatus for rinsing a microscope slide
US6083726A (en) 1998-02-03 2000-07-04 Lucent Technologies, Inc. Methods for polynucleotide synthesis and articles for polynucleotide hybridization
US6451683B1 (en) * 2000-08-28 2002-09-17 Micron Technology, Inc. Damascene structure and method of making
US6670113B2 (en) * 2001-03-30 2003-12-30 Nanoprobes Enzymatic deposition and alteration of metals
JP2003038173A (ja) * 2001-05-18 2003-02-12 Takeda Chem Ind Ltd 抗体の選別方法、ハイブリドーマ、モノクローナル抗体及びその用途
GB0125532D0 (en) 2001-10-24 2001-12-12 Burton Michael Enzyme activity indicators

Also Published As

Publication number Publication date
US20040265922A1 (en) 2004-12-30
CA2773566C (en) 2015-09-15
CA2530287C (en) 2012-06-19
DK1636586T3 (da) 2009-11-23
AU2004254386A1 (en) 2005-01-13
JP4648902B2 (ja) 2011-03-09
AU2004254386B2 (en) 2009-09-24
EP1636586B1 (de) 2009-07-22
ES2330441T3 (es) 2009-12-10
CA2530287A1 (en) 2005-01-13
JP2007528986A (ja) 2007-10-18
WO2005003777A3 (en) 2005-06-09
CA2773566A1 (en) 2005-01-13
EP1636586A2 (de) 2006-03-22
WO2005003777A2 (en) 2005-01-13
US7632652B2 (en) 2009-12-15
DE602004022165D1 (de) 2009-09-03

Similar Documents

Publication Publication Date Title
ATE437369T1 (de) Enzymkatalysierte metalldeposition zum verstärkten in-situ-nachweis von immunhistologischen epitopen und nukleinsäuresequenzen
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
Hartmann et al. Disturbance of DNA damage recognition after UV-irradiation by nickel (II) and cadmium (II) in mammalian cells.
ATE332505T1 (de) Verfahren und zusammensetzung zur auffindung von cervix-krebs
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
DK1092155T3 (da) Fremgangsmåde til tidlig diagnose af carcinomer
EP1379693A4 (de) Auf oligonukleotid-modifizierten partikeln basierende bio-strichcodes
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
Elsner et al. Burial condition is the most important factor for mtDNA PCR amplification success in Palaeolithic equid remains from the Alpine foreland
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드n―메틸트랜스퍼라아제의 용도
DK0757723T3 (da) Genetiske ændringer, der korrelerer med lungecarcinoma
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
EP2621942A2 (de) Mittel zur bereitstellung von kontrollen und standards für immunpräzipitationsassays
WO2015138532A2 (en) Methods for the treatment of kidney fibrosis
Namdarghanbari et al. Toxic metal proteomics: Reaction of the mammalian zinc proteome with Cd2+
JP2008537112A5 (de)
DE602004030041D1 (de) Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen
ATE319735T1 (de) Aufreinigung von substanzen aus einer biologischen probe
WO2004069860A3 (en) Isg15-conjugated proteins
EP1265073A3 (de) Verfahren zum Nachweis von der Plasmakonzentration von freien Arzneimitteln
ATE449868T1 (de) Methoden, testsätze und kompositionen zur detektion und quantifizierung von zielsequenzen
ATE432469T1 (de) Auf immunreaktion gegen boris basierendes verfahren für den nachweis von krebs
ATE272718T1 (de) Verfahren zur bestimmung von disaccharidasen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1636586

Country of ref document: EP